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Introduction
Activating somatic mutations in the BRAF protooncogene were
recently discovered in a wide variety of malignancies, and most
notably so in melanoma (?60%–70% of cases) (Brose et al.,
2002; Davies et al., 2002; Satyamoorthy et al., 2003), papillary
thyroid cancer (?35%–70%) (Cohen et al., 2003; Kimura et al.,
2003), and colon cancer (?10%) (Davies et al., 2002;
Rajagopalan et al., 2002; Yuen et al., 2002). Tumor-derived
BRAF alleles encode oncoproteins with constitutive serine/thre-
onine kinase activity, and when ectopically expressed in immor-
talized cell lines, they cause hyperstimulation of the MAP kinase
cascade and cellular transformation (Davies et al., 2002).
Preliminary studies suggest that B-Raf is a promising target for
drug development in melanoma and other malignancies that
depend upon B-Raf signaling.
The potential importance of mutant BRAF alleles in tumori-
genesis becomes apparent upon examining the function of Raf
kinases in normal cellular physiology (see Table 1 and Figure
1). BRAF is a member of the Raf family of protein kinases,
which includes CRAF, BRAF, and ARAF (Chong et al., 2003;
Mercer and Pritchard, 2003). Expression of all three RAF genes
can be detected in most tissues, with prominent expression of
BRAF in neuronal tissue and ARAF in urogenital tissue. The
entire RAF gene family is necessary for normal murine develop-
ment, with the expression of both CRAF and BRAF required to
complete gestation (Chong et al., 2003; Mercer and Pritchard,
2003). A diverse number of stimuli such as mitogens, hor-
mones, and neurotransmitters promote the activation of Raf
kinases by first triggering increases in the levels of Ras-GTP in
cells. The GTP-bound forms of Ras directly bind and thereby
recruit cytosolic dimers of Raf kinases to the plasma mem-
brane, where Raf is activated through phosphorylation by other
kinases and potentially by autophosphorylation (Chong et al.,
2003; Mercer and Pritchard, 2003). Activated and membrane-
associated Raf assembles a MAP kinase signaling complex that
consists of two classes of kinases, MEK and ERK, and scaffold-
ing proteins, including KSR, CNK, and RKIP (Chong et al.,
2003). The MAP kinase cascade initiates with the phosphoryla-
tion and activation of MEK by Raf, and the subsequent phos-
phorylation and activation of ERK by MEK. Active ERK
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Figure 1. Activation of the Raf/MEK/ERK MAP
kinase cascade
Step 1: mitogenic growth factors induce RTK
dimerization and activation, including the
recruitment of Grb2 and SOS to the plasma
membrane. 
Step 2: SOS activates Ras proteins by catalyzing
GTP exchange for GDP. 
Step 3: recruitment of inactive cytosolic Raf
homodimers to the plasma membrane by Ras-
GTP. 
Step 4: Activation of membrane-associated Raf
homodimers by phosphorylation. 
Step 5: MAP kinase complex comprised of
active Raf, scaffolding proteins such as KSR and
CNK (light blue), and MEK and ERK. Sequential
phosphorylation and activation of MEK, then
ERK. 
Step 6: translocation of active ERK to the nucle-
us and phosphorylation of multiple transcription
factors such as ELK. 
Step 7: transcriptional activation by phosphory-
lated transcription factors. Mutant B-Raf does
not depend on plasma membrane-associated
Ras-GTP and may be active in other cellular
compartments (not shown).
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dissociates from the Raf/MEK/ERK complex and phosphory-
lates a number of cytoskeletal proteins, kinases, and transcrip-
tion factors (Chong et al., 2003; Mercer and Pritchard, 2003)
(see Figure 1). The functional consequences of substrate phos-
phorylation by ERK are dependent upon cellular context and
include alterations in cellular motility and a multitude of gene
expression changes that promote proliferation, differentiation,
cellular survival, immortalization, and angiogenesis (Mercer
and Pritchard, 2003).
Although oncogenic forms of all three RAF family members
can be experimentally produced and several have been isolated
from transforming retroviruses, the exclusive identification of
somatic activating mutations in BRAF indicates unique proper-
ties for this paralog in cellular physiology and oncogenesis. B-
Raf has substantially greater basal kinase activity toward MEK
than does C-Raf or A-Raf (Chong et al., 2003; Mercer and
Pritchard, 2003). These differences between C-Raf and B-Raf
may relate to the finding that C-Raf contains four distinct Ras-
GTP-dependent phosphorylation sites for maximal activation
(S338, Y341, T491, and S494), whereas B-Raf possesses only
two of these sites (S598 and T601) (Chong et al., 2003; Mercer
and Pritchard, 2003).This provides the molecular shortcut for B-
Raf to become activated by a single amino acid substitution.
Indeed, the BRAFV599E missense mutation, which represents
over 80% of the oncogenic BRAF alleles described to date,
engenders constitutive and maximal activation of the B-Raf
kinase activity, likely by mimicking the phosphorylation of
S598/T601 in native B-Raf (Davies et al., 2002). The remaining
oncogenic BRAF mutations cluster near the V599 site or in the
G loop ATP binding region at residues 463–468.
Tissue-specific properties of oncogenic BRAF
The finding of BRAF mutations in a high percentage
(?60%–70%) of cutaneous melanomas was somewhat surpris-
ing, as prior studies could attribute hyperactivation of the mito-
genic receptor tyrosine kinase (RTK)-Ras-Raf-MAP kinase
pathway in melanoma to the abundance of autocrine and
paracrine growth factors (Lazar-Molnar et al., 2000), and to N-ras
mutations (Herlyn and Satyamoorthy, 1996). Indeed, a recent
report demonstrated that BRAF mutation is not a requisite event
in a specific type of melanoma, with no BRAF mutations detected
in 48 uveal melanomas (Edmunds et al., 2003). As uveal
melanoma also differs from cutaneous melanoma in that the for-
mer has frequent chromosome 6 abnormalities (Metzelaar-Blok
et al., 1999), it was predictable that distinct pathways for
melanoma formation exist. Future studies will be needed to deter-
mine whether the prevalence of BRAF mutations in melanoma
correlates with the site of the primary tumor and sun
exposure/sunburn, a known risk factor for cutaneous melanoma.
Also, it will be important to seek a molecular understanding of
those melanomas that do not harbor BRAF or RAS mutations.
Perhaps even more unexpected was the demonstration that
the BRAFV599E allele could be detected in as many as 80% of
benign nevi, suggesting a role for oncogenic BRAF in nevus for-
mation and melanoma initiation (Pollock et al., 2003). However,
a proposed role for oncogenic BRAFV599E in tumor initiation con-
flicts with the finding that constitutive hyperactivation of Raf pro-
teins causes premature senescence of primary human
fibroblasts in culture (Zhu et al., 1998).There is currently no evi-
dence that the benign nevi harboring BRAFV599E actually
progress to malignancy. In fact, the majority may represent non-
progressing terminally differentiated lesions that are analogous
to nondysplastic colorectal aberrant crypt foci (ACF) (Takayama
et al., 2001; Yamashita et al., 1995). Nondysplastic ACF harbor
KRAS mutations in the absence of APC mutations and are gen-
erally considered to have a low malignant potential, whereas
KRAS mutations that occur following APC mutation promote
colorectal tumor progression (Takayama et al., 2001;Yamashita
et al., 1995). Therefore, investigations into the function of
BRAFV599E in benign and dysplastic nevi may yield important
information about the type and timing of other genetic events
necessary for melanoma genesis.
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Table 1. Characteristics of the RAF family members
Isoform CRAF BRAF ARAF
Expression broad broad; high neurons broad; high urogenital
Development required required postnatal defects
Distant orthologs − + −
Kinase activation 4 sites 2 sites 4 sites
MEK stimulation ++ +++ +
Oncogenic ++ +++ +
Somatic mutations − + −
Figure 2. Structure of the BRAF gene, denoting the three conserved regions by thick blue bars
The Ras-GTP binding site is shown, as is the kinase domain. Common oncogenic mutations are denoted by triangles and corresponding amino acid
changes.
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Besides melanoma, several other tumor types are worthy of
mention with regards to BRAF mutation. Colorectal cancers
harbor mutant BRAF alleles in 4%–10% of the tumors
(Rajagopalan et al., 2002;Yuen et al., 2002), with the majority of
these mutations being BRAFV599E. A strong association exists
between mismatch repair deficiency and the presence of
BRAFV599E in colorectal cancer, which is possibly explained by
the underlying DNA repair defect (Rajagopalan et al., 2002).
Additionally, there is a mutual exclusivity of BRAFV599E and
KRAS mutations in tumor specimens, perhaps reflecting a
redundant function of these two oncogenes and emphasizing
the importance of the B-Raf pathway in oncogenic K-Ras sig-
naling (Rajagopalan et al., 2002). In this regard, it will be impor-
tant to evaluate the temporal sequence of BRAF mutation in
colorectal tumorigenesis. For example, if BRAF and KRAS are
truly interchangeable, then BRAF mutations should also be rep-
resented in colonic aberrant crypt foci that harbor wild-type
KRAS alleles. Also reflecting the redundancy of the RTK-Ras-
Raf-MAP kinase cascade, a substantial fraction of papillary thy-
roid cancer specimens harbor either BRAFV599E, mutant KRAS,
or mutant RET receptor tyrosine kinase (Cohen et al., 2003;
Kimura et al., 2003), and a large fraction of low grade ovarian
tumors harbor either BRAFV599E or mutant KRAS (Davies et al.,
2002; Singer et al., 2003). Other tumors that harbor mutant
BRAF alleles include cholangiocarcinoma (Tannapfel et al.,
2003) and lung adenocarcinoma (Brose et al., 2002; Naoki et
al., 2002). Of note, concomitant RAS mutations have been
demonstrated in cancer specimens that harbor the uncommon
G loop region BRAF mutations, suggesting differences in
molecular pathway utilization by distinct mutant B-Raf proteins
(Davies et al., 2002) (see Figure 2).
Oncogenic BRAF as a target for cancer therapeutics
Despite the large number of genetic alterations in cancer cells
and their microenvironment, recent evidence demonstrates that
the specific inhibition of a single critical pathway in tumor cells is
sufficient to cause cell death and clinical response in several
malignancies. For example, most patients with either chronic
myelogenous leukemia (CML) or gastrointestinal stromal tumor
(GIST) initially respond to monotherapy treatment with Imatinib
mesylate (Gleevec, STI571), a small molecule inhibitor of the
Abl and KIT tyrosine kinases (Demetri et al., 2002; Druker et al.,
2001). As predicted, the responsiveness of CML and GIST
patients to Gleevec directly correlates with the inhibition of the
tyrosine kinase activity of Bcr-Abl and mutant KIT, respectively
(Gorre et al., 2001; Tuveson et al., 2001). The development and
effectiveness of Imatinib in CML and GIST patients suggests
that therapies that specifically target other essential oncogenic
pathways may have similar efficacy and minimal toxicity.
Inhibition of the B-Raf kinase therefore represents a rational
therapeutic strategy in melanoma that is analogous to Bcr-Abl
and KIT inhibition by Imatinib in CML and GIST, respectively.
Indeed, an orally administered Raf kinase inhibitor, BAY 43-
9006 (Lyons et al., 2001), is currently undergoing worldwide
clinical evaluation in phase I and phase II trials in patients with a
variety of malignancies, including melanoma. BAY 43-9006
inhibits both B-Raf and C-Raf (G. Bollag, personal communica-
tion), and therefore any effects of drug treatment may be attrib-
utable to effects on both kinases simultaneously. The early
results from a phase I trial that combined BAY 43-9006 and the
chemotherapeutic agents carboplatin and paclitaxel were pre-
sented recently (K.T. Flaherty et al., 2003, Proc. Am. Soc. Clin.
Oncol., abstract #2854). Out of ten evaluable melanoma
patients, three were described as having anatomic partial
responses and six as having stable disease after at least two
cycles of treatment for all ten patients. Notably, this level of
responsiveness is superior to the results previously obtained
from melanoma patients treated with these chemotherapeutic
agents alone (Hodi et al., 2002). Correlative laboratory studies
are currently investigating whether BRAF mutation status and
MAP kinase pathway inhibition are predictive of clinical respon-
siveness to BAY 43-9006 in melanoma. Additionally, ongoing
clinical trials are evaluating BAY 43-9006 as a single agent in
melanoma patients.
Furthermore, recent preclinical findings in our own laborato-
ries support the prediction that melanoma cells harboring
mutant BRAF alleles are dependent upon continuous oncogene
function. Following the knockdown of BRAFV599E levels with RNA
interference methods, melanoma cells demonstrated profound
inhibition of the MAP kinase cascade, diminished proliferative
capacity, and the inability to support anchorage-independent
growth. Significantly, these effects were not recapitulated follow-
ing CRAF knockdown (S. Hingorani, M. Jacobetz, G. Robertson,
M.H., and D.T., unpublished data). Currently, we are attempting
to extend these observations to in vivo model systems.
Therefore, two approaches—kinase inhibition and protein
depletion—are potential methods to target oncogenic B-Raf
protein function. In addition to BAY 43-9006, Raf kinase
inhibitors specific for B-Raf will be of great interest to evaluate
when they become available. Furthermore, the existence of
multiple Raf kinase inhibitors with different chemical structures
and/or distinct modes of action is important because single
agent Raf kinase inhibition will likely lead to the emergence of
disease resistance in patients that initially respond, in analogy
to patients with CML and GIST treated with Gleevec (Demetri et
al., 2002; Druker et al., 2001; Hingorani and Tuveson, 2003).
Finally, B-Raf protein depletion is worthy of pursuit as a thera-
peutic strategy. RNA interference is not yet a clinically viable
approach, but may be in the near future. Alternatively, strategies
that decrease the stability of B-Raf protein can be explored. For
example, B-Raf is one of many proteins that binds to the molec-
ular chaperone and heat shock protein Hsp90 (Jaiswal et al.,
1996), and Hsp90 inhibitors have previously been shown to
decrease the stability and thus the oncogenic phenotypes of
various Bcr-Abl alleles in cell culture (Gorre et al., 2002).
In the year since the first description of activating BRAF
mutations in cancer, laboratory investigations and clinical trials
have provided an initial glimpse of this oncogene’s role in cells
and patients. This multidisciplinary translational research
approach illuminates the great progress we have made as a
community since the “War on Cancer” began some 30 years
ago. Furthermore, the identification of mutant BRAF alleles may
also serve as an example of the potential for large scale genom-
ic screening efforts, long considered “fishing expeditions,” to
produce important, novel therapeutic targets that move rapidly
into the clinic. Now is the time to clarify the role of this oncogene
in tumorigenesis and to expeditiously identify the most effica-
cious therapies for patients afflicted with malignancies that har-
bor BRAF mutations.
Acknowledgments
We apologize to our colleagues for our inability to cite multiple primary refer-
ences due to space limitations. This work is supported in part by the McCabe
Foundation, the Mary L. Smith Charitable Lead Trust, the Abramson Cancer
F O C U S
98 CANCER CELL : AUGUST 2003
Center of the University of Pennsylvania Pilot Projects Program, and Grant
#IRG-78-002-26 from the American Cancer Society (all to D.A.T.), by the NIH
grants CA-25874, CA-47159, CA-76674, and CA-10815 (to M.H.), and by funds
from the Abramson Family Cancer Research Institute (D.A.T. and B.L.W.).
References
Brose, M.S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn,
E., Herlyn, M., Minna, J., Nicholson, A., et al. (2002). BRAF and RAS muta-
tions in human lung cancer and melanoma. Cancer Res. 62, 6997–7000.
Chong, H., Vikis, H.G., and Guan, K.L. (2003). Mechanisms of regulating the
Raf kinase family. Cell. Signal. 15, 463–469.
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra,
W.H., Ladenson, P.W., and Sidransky, D. (2003). BRAF mutation in papillary
thyroid carcinoma. J. Natl. Cancer Inst. 95, 625–627.
Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S.,
Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. (2002).
Mutations of the BRAF gene in human cancer. Nature 417, 949–954.
Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D.,
Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S.,
Janicek, M., et al. (2002). Efficacy and safety of imatinib mesylate in
advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480.
Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M.,
Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers,
C.L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyro-
sine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037.
Edmunds, S.C., Cree, I.A., Di Nicolantonio, F., Hungerford, J.L., Hurren, J.S.,
and Kelsell, D.P. (2003). Absence of BRAF gene mutations in uveal
melanomas in contrast to cutaneous melanomas. Br. J. Cancer 88,
1403–1405.
Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N.,
and Sawyers, C.L. (2001). Clinical resistance to STI-571 cancer therapy
caused by BCR-ABL gene mutation or amplification. Science 293, 876–880.
Gorre, M.E., Ellwood-Yen, K., Chiosis, G., Rosen, N., and Sawyers, C.L.
(2002). BCR-ABL point mutants isolated from patients with imatinib mesy-
late-resistant chronic myeloid leukemia remain sensitive to inhibitors of the
BCR-ABL chaperone heat shock protein 90. Blood 100, 3041–3044.
Herlyn, M., and Satyamoorthy, K. (1996). Activated ras:Yet another player in
melanoma? Am. J. Pathol. 149, 739–744.
Hingorani, S.R., and Tuveson, D.A. (2003). Targeting oncogene dependence
and resistance. Cancer Cell 3, 414–417.
Hodi, F.S., Soiffer, R.J., Clark, J., Finkelstein, D.M., and Haluska, F.G. (2002).
Phase II study of paclitaxel and carboplatin for malignant melanoma. Am. J.
Clin. Oncol. 25, 283–286.
Jaiswal, R.K., Weissinger, E., Kolch, W., and Landreth, G.E. (1996). Nerve
growth factor-mediated activation of the mitogen-activated protein (MAP)
kinase cascade involves a signaling complex containing B-Raf and HSP90.
J. Biol. Chem. 271, 23626–23629.
Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E., and Fagin,
J.A. (2003). High prevalence of BRAF mutations in thyroid cancer: genetic
evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling
pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454–1457.
Lazar-Molnar, E., Hegyesi, H., Toth, S., and Falus, A. (2000). Autocrine and
paracrine regulation by cytokines and growth factors in melanoma. Cytokine
12, 547–554.
Lyons, J.F., Wilhelm, S., Hibner, B., and Bollag, G. (2001). Discovery of a
novel Raf kinase inhibitor. Endocr. Relat. Cancer 8, 219–225.
Mercer, K.E., and Pritchard, C.A. (2003). Raf proteins and cancer: B-Raf is
identified as a mutational target. Biochim. Biophys. Acta 1653, 25–40.
Metzelaar-Blok, J.A., Jager, M.J., Moghaddam, P.H., van der Slik, A.R., and
Giphart, M.J. (1999). Frequent loss of heterozygosity on chromosome 6p in
uveal melanoma. Hum. Immunol. 60, 962–969.
Naoki, K., Chen, T.H., Richards, W.G., Sugarbaker, D.J., and Meyerson, M.
(2002). Missense mutations of the BRAF gene in human lung adenocarcino-
ma. Cancer Res. 62, 7001–7003.
Pollock, P.M., Harper, U.L., Hansen, K.S., Yudt, L.M., Stark, M., Robbins,
C.M., Moses, T.Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003). High
frequency of BRAF mutations in nevi. Nat. Genet. 33, 19–20.
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K.W., Vogelstein, B., and
Velculescu, V.E. (2002). Tumorigenesis: RAF/RAS oncogenes and mis-
match-repair status. Nature 418, 934.
Satyamoorthy, K., Li, G., Gerrero, M.R., Brose, M.S., Volpe, P., Weber, B.L.,
Van Belle, P., Elder, D.E., and Herlyn, M. (2003). Constitutive mitogen-acti-
vated protein kinase activation in melanoma is mediated by both BRAF
mutations and autocrine growth factor stimulation. Cancer Res. 63, 756–759.
Singer, G., Oldt, R., 3rd, Cohen, Y., Wang, B.G., Sidransky, D., Kurman, R.J.,
and Shih Ie, M. (2003). Mutations in BRAF and KRAS characterize the devel-
opment of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95,
484–486.
Takayama, T., Ohi, M., Hayashi, T., Miyanishi, K., Nobuoka, A., Nakajima, T.,
Satoh, T., Takimoto, R., Kato, J., Sakamaki, S., and Niitsu, Y. (2001). Analysis
of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma,
cancer, and familial adenomatous polyposis. Gastroenterology 121,
599–611.
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D.,
Witzigmann, H., Hauss, J., and Wittekind, C. (2003). Mutations of the BRAF
gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52,
706–712.
Tuveson, D.A., Willis, N.A., Jacks, T., Griffin, J.D., Singer, S., Fletcher, C.D.,
Fletcher, J.A., and Demetri, G.D. (2001). STI571 inactivation of the gastroin-
testinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
Oncogene 20, 5054–5058.
Yamashita, N., Minamoto, T., Ochiai, A., Onda, M., and Esumi, H. (1995).
Frequent and characteristic K-ras activation and absence of p53 protein
accumulation in aberrant crypt foci of the colon. Gastroenterology 108,
434–440.
Yuen, S.T., Davies, H., Chan, T.L., Ho, J.W., Bignell, G.R., Cox, C., Stephens,
P., Edkins, S., Tsui, W.W., Chan, A.S., et al. (2002). Similarity of the pheno-
typic patterns associated with BRAF and KRAS mutations in colorectal neo-
plasia. Cancer Res. 62, 6451–6455.
Zhu, J., Woods, D., McMahon, M., and Bishop, J.M. (1998). Senescence of
human fibroblasts induced by oncogenic Raf. Genes Dev. 12, 2997–3007.
F O C U S
